Botond Szilagyi,Wei-Lee Wu,Ayse Eren,Jaron Mackey,Shivani Kshirsagar,Emoke Szilagyi,Iben Ostergaard,Haiyan Qu,Kushal Sinha,Laurie Mlinar,Daniel Pohlman,Jie Chen,Nandkishor Nere,Moussa Boukerche,Akshay Korde,Ryan Ellis,Michael Lovette,Simon Black,Anna Jawor-Baczynska,Huayu Li,Bing-Shiou Yang,Erwin Irdam,Daniel Patience,Rahn McKeown,Megan Ketchum,Daniel A. Green,Venkata Ramana Reddy,Christopher Polster,Christopher Burcham,Daniel Jarmer,Jeremy Miles Merritt,Aaron Cote,Eric Sirota,Lorenzo Codan,Jochen Schoell,Yiqing Claire Liu,Kevin P. Girard,Samir A. Kulkarni,Yihui Yang,Justin L. Quon,Zoltan K. Nagy

Abstract:Precompetitive collaborations on new enabling technologies for research and development are becoming popular among pharmaceutical companies. The Enabling Technologies Consortium (ETC), a precompetitive collaboration of leading innovative pharmaceutical companies, identifies and executes projects, often with third-party collaborators, to develop new tools and technologies of mutual interest. Here, we report the results of one of the first ETC projects: the development of a user-friendly population balance model (PBM)-based crystallization simulator software. This project required the development of PBM software with integrated experimental data handling, kinetic parameter regression, interactive process simulation, visualization, and optimization capabilities incorporated in a computationally efficient and robust software platform. Inputs from a team of experienced scientists at 10 ETC member companies helped define a set of software features that guided a team of crystallization modelers to develop software incorporating these features. Communication, continuous testing, and feedback between the ETC and the academic team facilitated the software development. The product of this project, a software tool called CrySiV, an acronym for Crystallization Simulation and Visualization, is reported herein. Currently, CrySiV can be used for cooling, antisolvent, and combined cooling and antisolvent crystallization processes, with primary and secondary nucleation, growth, dissolution, agglomeration, and breakage of crystals. This paper describes the features and the numerical methods of the software and presents two case studies demonstrating its use for parameter estimation. In the first case study, a simulated data set is used to demonstrate the capabilities of the software to find kinetic parameters and its goodness of fit to a known solution. In the second case study, the kinetics of an antisolvent crystallization of indomethacin from a ternary solvent system are estimated, providing a practical example of the tool.This article has not yet been cited by other publications.

Automated Self-Optimization of Continuous Crystallization of Nirmatrelvir API

Automated Continuous Crystallization Platform with Real-Time Particle Size Analysis via Laser Diffraction

Polymorphs, Particle Size, and a Pandemic: Development of a Scalable Crystallization Process for Molnupiravir, an Antiviral for the Treatment of COVID-19

Development of New Catalytic Asymmetric Routes towards a Cost-Driving Building Block of Nirmatrelvir

Inverse Method-Based Kinetic Modelling and Process Optimization of Reverse-Phase Chromatography for Molnupiravir Synthesis

Heterogeneous Crystallization as a Process Intensification Technology in an Integrated Continuous Manufacturing Process for Pharmaceuticals

Development of Continuous Filtration in a Novel Continuous Filtration Carousel Integrated with Continuous Crystallization

Cross-Pharma Collaboration for the Development of a Simulation Tool for the Model-Based Digital Design of Pharmaceutical Crystallization Processes (CrySiV)

Tale of Two Polymorphs: Investigating the Structural Differences and Dynamic Relationship between Nirmatrelvir Solid Forms (Paxlovid)

Integrated Continuous Process Design for Crystallisation, Spherical Agglomeration, and Filtration of Lovastatin

Enabling precision manufacturing of active pharmaceutical ingredients: workflow for seeded cooling continuous crystallisations

Scaling the Process Chemistry of a COVID-19 Antiviral Pharmaceutical Down for a Multistep Synthesis Experiment in the Undergraduate Teaching Laboratory

Tailoring the crystal size distribution of an active pharmaceutical ingredient by continuous antisolvent crystallization in a planar oscillatory flow crystallizer

Use of Wet Milling Combined with Temperature Cycling to Minimize Crystal Agglomeration in a Sequential Antisolvent-Cooling Crystallization

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations

Population balance model enabled digital design and uncertainty analysis framework for continuous crystallization of pharmaceuticals using an automated platform with full recycle and minimal material use

Compact Crystallization, Filtration, and Drying for the Production of Active Pharmaceutical Ingredients

Recent Progress in Continuous Crystallization of Pharmaceutical Products: Precise Preparation and Control

Developing and Optimizing a Quench-Crystallization Operation in Drug Substance Manufacturing

Designing Continuous Crystallization Protocols for Curcumin Using PAT Obtained Batch Kinetics

Strategy for Fast Decision on Material System Suitability for Continuous Crystallization Inside a Slug Flow Crystallizer